Adamas Healthcare Fund is a long/short equity fund, focusing exclusively on biotechnology and pharmaceutical companies. The fund emphasizes bottom-up research, based on rigorous scientific analysis. The fund invests in earlier stages of the drug development cycle, typically in small and mid-size companies. Investment focuses on positioning into specific catalysts, most commonly clinical trial outcomes and regulatory (FDA/EMA) decisions.  

Adamas Healthcare Fund has generated significant returns since inception in 2014, demonstrating superior performance relative to sector indices and strategy benchmarks

The fund’s research activities are centered around the therapeutic framework, capturing clinically driven alpha, while maintaining limited market correlation and low volatility. The combination of a strong scientific background and knowledge of each indication’s competitive landscape allows for meticulous statistical analysis of any given trial’s prior clinical data and current protocols, yielding solid convictions regarding the trial’s success probability and the drug’s future commercial viability.